New Alzheimer's drug shows 40% cognitive decline reduction in phase-3 trial
Henrik Lund
6 min read
Results from a large trial suggest the drug slows decline in early-stage patients.
A new Alzheimer's drug slowed cognitive decline by 40% in a large phase-3 trial, its makers said. The effect was strongest in patients treated early in the disease.
What happened
Independent experts called the results encouraging but want to see the full data and side-effect profile.
Why it matters
Regulators are expected to review the drug next year.
Key facts
A new Alzheimer's drug slowed cognitive decline by 40% in a large phase-3 trial, its makers said.
Independent experts called the results encouraging but want to see the full data and side-effect profile.
Health
Health, 2026
91,200
6 min read
